Register to receive a free U.S. Market Report Suite for Wound and Tissue Management report synopsis and brochure

SANUWAVE Health, Inc. recently announce that the company is entering into a Memorandum of Understanding with eKare, Inc. to develop novel wound care analysis and management solutions. Linking SANUWAVE’s dermaPACE® wound treatment device with eKare’s inSight® 3D wound imaging and analytics system, the two companies will strive to produce the industry’s most comprehensive wound management solution.

inSight uses the latest computer vision and 3D sensing technology to quickly and accurately assess the healing progress of wounds and feed that data into its AI (Artificial Intelligence) analytics engine to drive actionable insights. inSight is registered as a 510(k) Class I device and is CE Marked. SANUWAVE has long recognized that wound closure is but the end result of a series of evolving treatment decisions, made more complicated by a diabetic patient population. Leveraging eKare’s AI analytic platform, SANUWAVE will develop proprietary clinical decision support system for the dermaPACE solution to improve the outcome and lower the cost of wound care.

States Kevin Richardson, CEO of SANUWAVE, “Having conducted and analyzed two highly controlled wound studies, we have recognized that successful wound closure is dependent upon recognizing and adapting to multiple factors in a patient’s overall medical situation to effectively close wounds as quickly as possible. With eKare’s inSight, SANUWAVE believes that we have found the perfect platform for clinicians to manage the chess match that is wound closure.” Adds Travis Smith, Chief Commercial Officer of eKare, “We are excited to be teaming with SANUWAVE to elevate inSight’s strength in imaging and analytics to develop better treatment algorithms for the dermaPace solution. This potent combination of therapy, 3D imaging, and data analytics can pave the path to powerful and cost effective wound closure solutions.”

SANUWAVE dermaPACE, CE Marked and licensed in Canada, Australia, and South Korea has a proven record of effectiveness in treating skin conditions, particularly diabetic foot ulcers and venous leg ulcers. In the US, SANUWAVE has completed two US based clinical trials enrolling 336 subjects, which have proven the dermaPACE to be safe and effective in the treatment of Diabetic Foot Ulcers. Within a few weeks of initial treatment, wounds treated with dermaPACE reduce in area at superior rates compared to control subjects. dermaPACE exhibits superiority in wound area reduction within 12 weeks of initial treatment and exhibits superiority in wound closure within 20 weeks of initial treatment. Combined with the imaging and analytical power of inSight, the two companies intend to jump to the forefront in intelligent wound management and healing. SANUWAVE intends to introduce the inSight system into additional clinical trials planned for 2017.

For more information on SANUWAVE’s technology, please read our blog, “Shock This”, on our website at www.sanuwave.com. Additional information for eKare can be found on their website at www.ekareinc.com.

About SANUWAVE Health, Inc.
SANUWAVE Health, Inc. (OTCQB: SNWV) (www.sanuwave.com) is a shock wave technology company initially focused on the development and commercialization of patented noninvasive, biological response activating devices for the repair and regeneration of skin, musculoskeletal tissue and vascular structures. SANUWAVE’s portfolio of regenerative medicine products and product candidates activate biologic signaling and angiogenic responses, producing new vascularization and microcirculatory improvement, which helps restore the body’s normal healing processes and regeneration. SANUWAVE applies its patented PACE technology in wound healing, orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product candidate for the global wound care market, dermaPACE®, is CE Marked throughout Europe and has device license approval for the treatment of the skin and subcutaneous soft tissue in Canada, Australia and New Zealand. In the U.S., dermaPACE is currently under the FDA’s de novo petition review process for the treatment of diabetic foot ulcers. SANUWAVE researches, designs, manufactures, markets and services its products worldwide, and believes it has demonstrated that its technology is safe and effective in stimulating healing in chronic conditions of the foot (plantar fasciitis) and the elbow (lateral epicondylitis) through its U.S. Class III PMA approved OssaTron® device, as well as stimulating bone and chronic tendonitis regeneration in the musculoskeletal environment through the utilization of its OssaTron, Evotron® and orthoPACE® devices in Europe, Asia and Asia/Pacific. In addition, there are license/partnership opportunities for SANUWAVE’s shock wave technology for non-medical uses, including energy, water, food and industrial markets.

About eKare, Inc.
eKare Inc. (http://ekare.ai) is dedicated to the design and development of wound assessment solutions using the latest machine intelligence, computer-vision, and mobile technology. eKare’s current technology offering include wound tissue classification, mobile 3D imaging, as well as AI analytics engine to draw clinical insights and business intelligence. eKare’s innovative technology is creating new possibilities in how we deliver wound care across the healthcare continuum, from inpatient hospital and skilled nursing facilities to ambulatory clinics and telemedicine.

For Further Information
More on the wound tissue market in the U.S. can be found in a series of reports published by iData Research entitled the U.S. Market Report Suite for Wound and Tissue Management. The suite covers reports on the following markets: Wound Closure, Static Compression Therapy, Dynamic Compression Therapy, Advanced Dressings, Moist Dressings, Antimicrobial Dressings, Interactive Dressings, Non-Adherent Contact Layers, Traditional Wound Dressings, Hemostats, Tissue Sealants, Anti-Adhesion, and Negative Pressure Wound Therapy.

The iData report series on wound and tissue management covers the U.S., Japan, India, China and 15 countries in Europe including Austria, Belgium, Denmark, Finland, France, Germany, Italy, Luxembourg, Netherlands, Norway, Portugal, Spain, Sweden, the United Kingdom, and Switzerland. Reports provide a comprehensive analysis including units sold, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment. To find out more about wound tissue management market data, register online or email us at [email protected] for a U.S. Market Report Suite for Wound and Tissue Management brochure and synopsis.

About iData Research
iData Research is an international market research and consulting firm, dedicated to providing the best in business intelligence for the medical device industry. Our research empowers our clients by providing them with the necessary tools to achieve their goals and do it right the first time. iData covers research in: Laparoscopy, Urology, Gynecology, Endoscopy, Dental Operatory Equipment, Dental Material, Dental Lasers, Dental Prosthetics, Dental CAD/CAM, Dental Bone Graft Substitutes, Ophthalmics, Ultrasound, X-Ray Imaging, Diagnostic Imaging, Oncology, Vascular Access, Interventional Cardiology, Cardiac Surgery, Cardiac Rhythm Management, Electrophysiology, Operating Room Equipment, Surgical Microscopes, Robotics and Surgical Navigation, Spinal Implants and VCF, Spinal MIS, Orthopedic Soft Tissue Repair and Regeneration, Orthopedic Trauma, Large & Small Joints, Anesthesiology, Wound Management, Orthopedics and more.

We have built a reputation and earned our clients’ trust based on consistent and uniquely intelligent research that allows our customers to make confident decisions and impact their businesses. A combination of market expertise and over a decade of experience has resulted in a deep understanding of the medical device industry that has inspired innovation and propelled our clients to success.

About Procedure Tracker
Procedure number data is available from iData’s Procedure Tracker service, which allows subscribers to define and analyze procedure data segmented by state, region, hospital, surgery centre, and physician. A customizable dashboard sorts procedure data for further analysis and research.

About Reimbursement Tracker
iData Research’s Reimbursement Policy Tracker enables medical device, dental, pharmaceutical and healthcare professionals to receive real-time policy updates from hundreds of insurance companies and 60,000+ policies across all therapeutic areas in the United States.

About iPolicy Search
iPolicy Search allows medical device manufacturers and reimbursement consultants to drastically reduce their research time by searching an automatically updating database of policies from over 200 insurance groups in the United States.


Explore our careers page for our current available job opportunities. This is your chance to join a fun and dynamic team in the medical market research industry. Send your resume to [email protected] with the job title in the subject line, and feel free to tell us a little about yourself. We look forward to hearing from you.

Like us on Facebook: facebook.com/iDataResearch
Follow us on LinkedIn: linkedin.com/company/idata-research
Follow us on Twitter: twitter.com/iDataResearch